Skip to content

Treatment of Atrophic Nonunion by Preosteoblast Cells

Treatment of Refractory Non-union Fractures by Pre-osteoblast Cells Grafting : a Pilot Study.

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00916981
Enrollment
30
Registered
2009-06-10
Start date
2008-11-30
Completion date
2009-06-30
Last updated
2012-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fractures, Ununited, Pseudarthrosis

Keywords

pseudarthrosis, Treatment, osteoblast grafting, cell therapy, nonunion

Brief summary

Treatment of nonunion, delayed union and malunion fractures of long bones remains problematic. The definition of nonunion is a failure of the fracture to heal in six months in a patient in whom progressive repair had not been observed radiographically between the third and sixth month after the fracture. First of all good surgical techniques are stable immobilization must be obtained and local sepsis excluded. Then stimulation of the callus is required. Numerous techniques have been developed ranging from invasive interventions (including internal fixation with the use of bone graft or bone graft substitutes) to non invasive procedures (ultrasound and pulsed electromagnetic fields). Recently, autologous cell therapy was presented as an interesting approach. The concept of such therapies is based on the effect of stem cells presented in the bone marrow and able to be transformed in osteoblast cells. The percutaneous technique of autologous bone-marrow grafting is a minimally invasive alternative able to produce a good healing of the fracture. The efficacy is dependent of the concentration in progenitor cell reinjected. An optimization of this type of treatment could be achieved using a technique to increase the differentiation of the bone marrow cells in preosteoblasts before the injection in situ by an adequate culture. Therefore we would like to start a pilot open study on the feasibility and the efficacy of implantation of preosteoblasts into nonunion. Two different presentations exist: the atrophic and the hypertrophic pseudarthrosis in relationship with radiological features of bone proliferation at the tip of bone fragments. Some data support that atrophic and hypertrophic nonunion fractures could have different physiopathological factors. So, in a first time we only would evaluate the atrophic form and to determine in an open study the effect of the implantation of preosteoblasts into atrophic nonunion.

Detailed description

We will recruit 30 patients having a atrophic nonunion fracture of long bone present for minimum 6 months.50 ml of bone marrow harvest will be performed under local anaesthesia 3 weeks before the implantation. After three weeks of culture, preosteoblastic cells will be injected into the site of pseudarthrosis under radioscopic control, using percutaneously a 3 mm trephine. An immobilization and non weight-bearing of the bone will be respected during the first month after the injection. If callus could be observed on radiographs, partial mobilization and weight-bearing will be allowed during the second month.

Interventions

PROCEDUREpercutaneous autologous preosteoblast cells implantation

percutaneously injection of preosteoblast into the nonunion under radioscopic control

Sponsors

Jean-Philippe Hauzeur
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Fracture of a long bone having insufficient healing after minimum 6 months. * Be able and willing to participate in the study.

Exclusion criteria

* Evidence of malignant disorder in the past five year. * Patient who is positive for an HIV, hepatitis B or C infection. * Insufficient reduction of the fracture with displaced fragments. * Evidence of local sepsis by biological parameters and/or positive isotopic scan using leucocytes labelled by Indium.

Design outcomes

Primary

MeasureTime frameDescription
radiological progression of bone fusion1, 2, 3, 4, 5, 6 monthsmonthly

Secondary

MeasureTime frame
reduction of pain using VASeach month

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026